Thromb Haemost 1997; 77(06): 1179-1181
DOI: 10.1055/s-0038-1656134
Platelets
Schattauer GmbH Stuttgart

The Leu33/Pro Polymorphism (PIA1/PIA2 ) of the Glycoprotein IIIa (GPIIIa) Receptor Is Not Related to Myocardial Infarction in the ECTIM Study

Stefan-Martin Herrmann
The Institut National de la Santé et de la Recherche Médicale (Inserm) SC7, Paris
,
Odette Poirier
The Institut National de la Santé et de la Recherche Médicale (Inserm) SC7, Paris
,
Pedro Marques-Vidal
1   Monica Project Toulouse, France
,
Alun Evans
2   Monica Project Belfast, Northern Ireland, UK
,
Dominique Arveiler
3   Monica Project Strasbourg, Paris, France
,
Gerald Luc
4   Monica Project Lille, Paris, France
,
Joseph Emmerich
5   Hôpital Broussais, Paris, France
,
François Cambien
The Institut National de la Santé et de la Recherche Médicale (Inserm) SC7, Paris
› Institutsangaben
Weitere Informationen

Publikationsverlauf

Received 25. Oktober 1996

Accepted after resubmisssion 12. Februar 1997

Publikationsdatum:
26. Juli 2018 (online)

Summary

The GPIIb/IIIa receptor complex may contribute to acute coronary syndromes by mediating platelet aggregation. The Leu33/Pro polymorphism (PlAl/PlA2) of the GPIIIa has recently been shown to be associated with CHD in a small case-control study. We have investigated this polymorphism in a large multicenter study of patients with myocardial infarction and controls and found no difference in the distribution of allele and genotype frequencies between cases and controls.

 
  • References

  • 1 Fuster V, Badimon L, Badimon JJ, Chesebro JH. The pathogenesis of coronary artery disease and the acute coronary syndromes. N Engl J Med 1992; 326: 242-250
  • 2 The EPIC Investigators. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor complex in high-risk coronary angioplasty. N Engl J Med 1994; 330: 956-961
  • 3 Coller BS. Blockade of platelet GPIIb/IIIa receptors as an antithrombotic strategy. Circulation 1995; 92: 2373-2380
  • 4 Weiss EJ, Bray PF, Tayback M, Schulman SP, Kickler TS, Becker LC, Weiss JL, Gerstenblith G, Goldschmidt-Clermont PJ. A polymorphism of a platelet glycoprotein receptor as an inherited risk factor for coronary thrombosis. N Engl J Med 1996; 334: 1090-1094
  • 5 Parra HJ, Arveiler D, Evans AE, Cambou JP, Amouyel P, Bingham A, McMaster D, Schaffer P, Douste-Blazy P, Luc G, Richard JL, Ducimetiére P, Cambien F. A case-control study of lipoprotein particles in two populations at contrasting risk for coronary heart disease:the ECTIM Study. Arterioscler Thromb 1992; 12: 701-707
  • 6 Cambien F, Poirier O, Lecerf L, Evans A, Cambou JP, Arveiler D, Luc G, Bard JM, Bara L, Ricard S, Tiret L, Amouyel P, Alhenc-Gelas F, Soubrier F. Deletion polymorphism in the gene for angiotensin-converting enzyme is a potent risk factor for myocardial infarction. Nature 1992; 359: 641-644
  • 7 WHO MONICA Project principal investigators. The World Health Organization MONICA project (MONItoring trends and determinants in CArdiovascular disease):a major international collaboration. J Clin Epidemiol 1988; 41: 105-114
  • 8 Jin Y, Dietz HC, Nurden A, Bray PF. Single-strand conformation polymorphism analysis is a rapid and effective method for the identification of mutations and polymorphisms in the gene for glycoprotein IIIa. Blood 1993; 82: 2281-2288
  • 9 Saiki RK. Genetic analysis of enzymatically amplified β-globin and HLA-DQA genomic DNA with allele specific oligonucleotide probes. Nature 1987; 324: 163-166
  • 10 Marian AJ, Brugada R, Kleinman NS. Platelet glycoprotein IIIa PlA polymorphism and myocardial infarction. N Engl J Med 1996; 335: 1071-1072
  • 11 Carter AM, Osseigerning N, Grant PJ. Platelet glycoprotein IIIa PlA polymorphism and myocardial infarction. N Engl J Med 1996; 335: 1072-1073
  • 12 Osborn SV, Hampton KK, Smillie D, Channer KS, Daly ME. Platelet glycoprotein IIIa gene polymorphism and myocardial infarction. Lancet 1996; 348: 1309-1310
  • 13 Odawara M, Matsunuma A, Yamashita K. Platelet glycoprotein IIIa PlA polymorphism and Japanese diabetic patients with coronary heart disease. Lancet 1996; 348: 1310